Similar articles

• Prospects for mTOR targeting in adult T cell leukemia.

  Altman JK, Platanias LC. Altman JK, et al. Leuk Lymphoma. 2009 Apr;50(4):525-6. doi: 10.1080/10428190902741505. Leuk Lymphoma. 2009. PMID: 19373648 No abstract available.
• Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.

  Ikezoe T, Nishioka C, Bandobashi K, Yang Y, Kuwayama Y, Adachi Y, Takeuchi T, Koeffler HP, Taguchi H. Ikezoe T, et al. Leuk Res. 2007 May;31(5):673-82. doi: 10.1016/j.leukres.2006.08.001. Epub 2006 Sep 27. Leuk Res. 2007. PMID: 17007924
• Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

  Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA. Marzec M, et al. Oncogene. 2007 Aug 16;26(38):5606-14. doi: 10.1038/sj.onc.1210346. Epub 2007 Mar 12. Oncogene. 2007. PMID: 17353907
• [Advances on PI3K/Akt/mTOR signalling pathway in malignancies].

  Yu BH, Zhou XY. Yu BH, et al. Zhonghua Bing Li Xue Za Zhi. 2005 Oct;34(10):674-6. Zhonghua Bing Li Xue Za Zhi. 2005. PMID: 16536284 Review. Chinese. No abstract available.
• New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.

  Carraway H, Hidalgo M. Carraway H, et al. Breast Cancer Res. 2004;6(5):219-24. doi: 10.1186/bcr927. Epub 2004 Aug 12. Breast Cancer Res. 2004. PMID: 15318929 Free PMC article. Review.